Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Same Data, Same Day, Different Decision: FDA, EMA On Roche's Protease Inhibitor Invirase

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA goes for a new warning and a MedGuide; EMA calls for a lower starting dose.

You may also be interested in...

REMS Cannot Save Abbott's Obesity Drug Meridia In Face Of Cardiovascular Issues

Firm withdraws sibutramine as FDA finds no patient group for which risk mitigation would result in sufficient benefit.

FDA, EMA Decisions On Avandia Reflect The Power Of REMS

Contrasting decisions by FDA and the European Medicines Agency on the fate of GlaxoSmithKline’s Avandia reflect not so much a divergence of scientific opinion between the two regulators, but rather differences in how they chose to manage the drug’s cardiovascular risks and the tools available for doing so.

AstraZeneca's Ticagrelor Gets Positive EU Recommendation, But FDA Could Catch Up Soon

Europe's CHMP recommends ticagrelor for patients with acute coronary syndromes, while FDA still grapples with lack of effect in North American patients.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts